Women’s perspective of botulinum toxin treatment for overactive bladder symptoms
Introduction and hypothesis This study aimed to evaluate the women’s’ views and expectations about outcomes and complications of botulinum toxin treatment for overactive bladder (OAB) symptoms. Methods Consecutive women with OAB symptoms and detrusor overactivity were requested to fill out a multipl...
Gespeichert in:
| Veröffentlicht in: | International Urogynecology Journal 2011-04, Vol.22 (4), p.425-431 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 431 |
|---|---|
| container_issue | 4 |
| container_start_page | 425 |
| container_title | International Urogynecology Journal |
| container_volume | 22 |
| creator | Digesu, G. Alessandro Panayi, Demetri Hendricken, Caroline Camarata, Michelle Fernando, Ruwan Khullar, Vikram |
| description | Introduction and hypothesis
This study aimed to evaluate the women’s’ views and expectations about outcomes and complications of botulinum toxin treatment for overactive bladder (OAB) symptoms.
Methods
Consecutive women with OAB symptoms and detrusor overactivity were requested to fill out a multiple choice questionnaire to assess whether they would consider botulinum and what outcomes as well as complications they would find acceptable to undergo this treatment.
Results
Two hundred sixty-one women, mean age of 58 (range, 38–78) years, were studied. Two hundred twenty-four were treatment-naive women (group A), while 37 were no responders to anticholinergics (group B). Only 49.6% of women in group A and 54% in group B would accept botulinum toxin. No significant differences were found between treatment-naive women and non-responders to anticholinergics (
p
> 0.05).
Conclusions
Acceptance of botulinum toxin treatment involves a complex interaction of efficacy and possible complications. The balance of these factors changes the acceptability of the treatment. |
| doi_str_mv | 10.1007/s00192-010-1315-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_855944308</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2286703471</sourcerecordid><originalsourceid>FETCH-LOGICAL-c370t-9e2dea529a08ccb8a417d91d2eafb1895857f5aab3493fc206ac6c706db50c7f3</originalsourceid><addsrcrecordid>eNp1kMtKxDAUhoMozjj6AG6kuI-e3NpmKYM3GBBEcRnSNJUO06Ym6TCz8zV8PZ_EDvWycnU4nO__D3wInRK4IADZZQAgkmIggAkjAm_20JRwxjADyvbRFCTLMOMpnaCjEJYAwEHAIZpQQoBz4FP0-OIa236-f4Sksz501sR6bRNXJYWL_apu-yaJblO3SfRWx4GNSeV84tbW65EtVrosrU_Ctumia8IxOqj0KtiT7zlDzzfXT_M7vHi4vZ9fLbBhGUQsLS2tFlRqyI0pcs1JVkpSUqurguRS5CKrhNYF45JVhkKqTWoySMtCgMkqNkPnY2_n3VtvQ1RL1_t2eKlyISTnDPIBIiNkvAvB20p1vm603yoCaidRjRIV7PZBotoMmbPv4r5obPmb-LE2AHQEwnBqX63_-_x_6xcxL3-i</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>855944308</pqid></control><display><type>article</type><title>Women’s perspective of botulinum toxin treatment for overactive bladder symptoms</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Digesu, G. Alessandro ; Panayi, Demetri ; Hendricken, Caroline ; Camarata, Michelle ; Fernando, Ruwan ; Khullar, Vikram</creator><creatorcontrib>Digesu, G. Alessandro ; Panayi, Demetri ; Hendricken, Caroline ; Camarata, Michelle ; Fernando, Ruwan ; Khullar, Vikram</creatorcontrib><description>Introduction and hypothesis
This study aimed to evaluate the women’s’ views and expectations about outcomes and complications of botulinum toxin treatment for overactive bladder (OAB) symptoms.
Methods
Consecutive women with OAB symptoms and detrusor overactivity were requested to fill out a multiple choice questionnaire to assess whether they would consider botulinum and what outcomes as well as complications they would find acceptable to undergo this treatment.
Results
Two hundred sixty-one women, mean age of 58 (range, 38–78) years, were studied. Two hundred twenty-four were treatment-naive women (group A), while 37 were no responders to anticholinergics (group B). Only 49.6% of women in group A and 54% in group B would accept botulinum toxin. No significant differences were found between treatment-naive women and non-responders to anticholinergics (
p
> 0.05).
Conclusions
Acceptance of botulinum toxin treatment involves a complex interaction of efficacy and possible complications. The balance of these factors changes the acceptability of the treatment.</description><identifier>ISSN: 0937-3462</identifier><identifier>EISSN: 1433-3023</identifier><identifier>DOI: 10.1007/s00192-010-1315-x</identifier><identifier>PMID: 21104404</identifier><language>eng</language><publisher>London: Springer-Verlag</publisher><subject>Adult ; Aged ; Anti-Dyskinesia Agents - adverse effects ; Anti-Dyskinesia Agents - therapeutic use ; Botulinum Toxins - adverse effects ; Botulinum Toxins - therapeutic use ; Female ; Gynecology ; Humans ; Medicine ; Medicine & Public Health ; Middle Aged ; Original Article ; Patient Acceptance of Health Care - psychology ; Patient Acceptance of Health Care - statistics & numerical data ; Prospective Studies ; Urinary Bladder, Overactive - drug therapy ; Urology</subject><ispartof>International Urogynecology Journal, 2011-04, Vol.22 (4), p.425-431</ispartof><rights>The International Urogynecological Association 2010</rights><rights>The International Urogynecological Association 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c370t-9e2dea529a08ccb8a417d91d2eafb1895857f5aab3493fc206ac6c706db50c7f3</citedby><cites>FETCH-LOGICAL-c370t-9e2dea529a08ccb8a417d91d2eafb1895857f5aab3493fc206ac6c706db50c7f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00192-010-1315-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00192-010-1315-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21104404$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Digesu, G. Alessandro</creatorcontrib><creatorcontrib>Panayi, Demetri</creatorcontrib><creatorcontrib>Hendricken, Caroline</creatorcontrib><creatorcontrib>Camarata, Michelle</creatorcontrib><creatorcontrib>Fernando, Ruwan</creatorcontrib><creatorcontrib>Khullar, Vikram</creatorcontrib><title>Women’s perspective of botulinum toxin treatment for overactive bladder symptoms</title><title>International Urogynecology Journal</title><addtitle>Int Urogynecol J</addtitle><addtitle>Int Urogynecol J</addtitle><description>Introduction and hypothesis
This study aimed to evaluate the women’s’ views and expectations about outcomes and complications of botulinum toxin treatment for overactive bladder (OAB) symptoms.
Methods
Consecutive women with OAB symptoms and detrusor overactivity were requested to fill out a multiple choice questionnaire to assess whether they would consider botulinum and what outcomes as well as complications they would find acceptable to undergo this treatment.
Results
Two hundred sixty-one women, mean age of 58 (range, 38–78) years, were studied. Two hundred twenty-four were treatment-naive women (group A), while 37 were no responders to anticholinergics (group B). Only 49.6% of women in group A and 54% in group B would accept botulinum toxin. No significant differences were found between treatment-naive women and non-responders to anticholinergics (
p
> 0.05).
Conclusions
Acceptance of botulinum toxin treatment involves a complex interaction of efficacy and possible complications. The balance of these factors changes the acceptability of the treatment.</description><subject>Adult</subject><subject>Aged</subject><subject>Anti-Dyskinesia Agents - adverse effects</subject><subject>Anti-Dyskinesia Agents - therapeutic use</subject><subject>Botulinum Toxins - adverse effects</subject><subject>Botulinum Toxins - therapeutic use</subject><subject>Female</subject><subject>Gynecology</subject><subject>Humans</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Original Article</subject><subject>Patient Acceptance of Health Care - psychology</subject><subject>Patient Acceptance of Health Care - statistics & numerical data</subject><subject>Prospective Studies</subject><subject>Urinary Bladder, Overactive - drug therapy</subject><subject>Urology</subject><issn>0937-3462</issn><issn>1433-3023</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kMtKxDAUhoMozjj6AG6kuI-e3NpmKYM3GBBEcRnSNJUO06Ym6TCz8zV8PZ_EDvWycnU4nO__D3wInRK4IADZZQAgkmIggAkjAm_20JRwxjADyvbRFCTLMOMpnaCjEJYAwEHAIZpQQoBz4FP0-OIa236-f4Sksz501sR6bRNXJYWL_apu-yaJblO3SfRWx4GNSeV84tbW65EtVrosrU_Ctumia8IxOqj0KtiT7zlDzzfXT_M7vHi4vZ9fLbBhGUQsLS2tFlRqyI0pcs1JVkpSUqurguRS5CKrhNYF45JVhkKqTWoySMtCgMkqNkPnY2_n3VtvQ1RL1_t2eKlyISTnDPIBIiNkvAvB20p1vm603yoCaidRjRIV7PZBotoMmbPv4r5obPmb-LE2AHQEwnBqX63_-_x_6xcxL3-i</recordid><startdate>20110401</startdate><enddate>20110401</enddate><creator>Digesu, G. Alessandro</creator><creator>Panayi, Demetri</creator><creator>Hendricken, Caroline</creator><creator>Camarata, Michelle</creator><creator>Fernando, Ruwan</creator><creator>Khullar, Vikram</creator><general>Springer-Verlag</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>20110401</creationdate><title>Women’s perspective of botulinum toxin treatment for overactive bladder symptoms</title><author>Digesu, G. Alessandro ; Panayi, Demetri ; Hendricken, Caroline ; Camarata, Michelle ; Fernando, Ruwan ; Khullar, Vikram</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c370t-9e2dea529a08ccb8a417d91d2eafb1895857f5aab3493fc206ac6c706db50c7f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anti-Dyskinesia Agents - adverse effects</topic><topic>Anti-Dyskinesia Agents - therapeutic use</topic><topic>Botulinum Toxins - adverse effects</topic><topic>Botulinum Toxins - therapeutic use</topic><topic>Female</topic><topic>Gynecology</topic><topic>Humans</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Original Article</topic><topic>Patient Acceptance of Health Care - psychology</topic><topic>Patient Acceptance of Health Care - statistics & numerical data</topic><topic>Prospective Studies</topic><topic>Urinary Bladder, Overactive - drug therapy</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Digesu, G. Alessandro</creatorcontrib><creatorcontrib>Panayi, Demetri</creatorcontrib><creatorcontrib>Hendricken, Caroline</creatorcontrib><creatorcontrib>Camarata, Michelle</creatorcontrib><creatorcontrib>Fernando, Ruwan</creatorcontrib><creatorcontrib>Khullar, Vikram</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>International Urogynecology Journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Digesu, G. Alessandro</au><au>Panayi, Demetri</au><au>Hendricken, Caroline</au><au>Camarata, Michelle</au><au>Fernando, Ruwan</au><au>Khullar, Vikram</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Women’s perspective of botulinum toxin treatment for overactive bladder symptoms</atitle><jtitle>International Urogynecology Journal</jtitle><stitle>Int Urogynecol J</stitle><addtitle>Int Urogynecol J</addtitle><date>2011-04-01</date><risdate>2011</risdate><volume>22</volume><issue>4</issue><spage>425</spage><epage>431</epage><pages>425-431</pages><issn>0937-3462</issn><eissn>1433-3023</eissn><abstract>Introduction and hypothesis
This study aimed to evaluate the women’s’ views and expectations about outcomes and complications of botulinum toxin treatment for overactive bladder (OAB) symptoms.
Methods
Consecutive women with OAB symptoms and detrusor overactivity were requested to fill out a multiple choice questionnaire to assess whether they would consider botulinum and what outcomes as well as complications they would find acceptable to undergo this treatment.
Results
Two hundred sixty-one women, mean age of 58 (range, 38–78) years, were studied. Two hundred twenty-four were treatment-naive women (group A), while 37 were no responders to anticholinergics (group B). Only 49.6% of women in group A and 54% in group B would accept botulinum toxin. No significant differences were found between treatment-naive women and non-responders to anticholinergics (
p
> 0.05).
Conclusions
Acceptance of botulinum toxin treatment involves a complex interaction of efficacy and possible complications. The balance of these factors changes the acceptability of the treatment.</abstract><cop>London</cop><pub>Springer-Verlag</pub><pmid>21104404</pmid><doi>10.1007/s00192-010-1315-x</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0937-3462 |
| ispartof | International Urogynecology Journal, 2011-04, Vol.22 (4), p.425-431 |
| issn | 0937-3462 1433-3023 |
| language | eng |
| recordid | cdi_proquest_journals_855944308 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Anti-Dyskinesia Agents - adverse effects Anti-Dyskinesia Agents - therapeutic use Botulinum Toxins - adverse effects Botulinum Toxins - therapeutic use Female Gynecology Humans Medicine Medicine & Public Health Middle Aged Original Article Patient Acceptance of Health Care - psychology Patient Acceptance of Health Care - statistics & numerical data Prospective Studies Urinary Bladder, Overactive - drug therapy Urology |
| title | Women’s perspective of botulinum toxin treatment for overactive bladder symptoms |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T03%3A00%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Women%E2%80%99s%20perspective%20of%20botulinum%20toxin%20treatment%20for%20overactive%20bladder%20symptoms&rft.jtitle=International%20Urogynecology%20Journal&rft.au=Digesu,%20G.%20Alessandro&rft.date=2011-04-01&rft.volume=22&rft.issue=4&rft.spage=425&rft.epage=431&rft.pages=425-431&rft.issn=0937-3462&rft.eissn=1433-3023&rft_id=info:doi/10.1007/s00192-010-1315-x&rft_dat=%3Cproquest_cross%3E2286703471%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=855944308&rft_id=info:pmid/21104404&rfr_iscdi=true |